Brian Johnson, thanks for being here. >> Yeah, it's good to see you. >> How are you feeling.Maybe just share with us what you did a few days ago. And >> yeah, I did um a I did five MOD DMT, which is the most powerful psychedelic on the planet. Uh it's somewhere between five and 10 times more powerful than DMT.And so, yeah, I it's so it's been 48 hours. I'm still learning how to talk about it. >> You know what.Many of the biggest tech CEOs and VCs have in common. They sleep on the Pod by eight sleep. It's be ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on March 24, 2026. Registration No. 333-290086 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPTIMI HEALTH CORP. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) (State or other jurisdiction of incorporation or organization) British Columbia 2834 Not Applic ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on March 13, 2026. Registration No. 333-290086 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPTIMI HEALTH CORP. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) (State or other jurisdiction of incorporation or organization) British Columbia 2834 Not Applic ...

Core Insights - Psyence Biomedical Ltd. emphasizes the importance of strategic investments in building a robust pharmaceutical-grade manufacturing and supply chain infrastructure, particularly through its investment in PsyLabs, which is crucial for competitiveness in the psychedelic pharmaceutical sector [1][2][9]. Company Strategy - The investment in PsyLabs has enabled Psyence BioMed to secure scalable pharmaceutical-grade manufacturing capabilities, which are essential as the psychedelic therapeutics sector matures [2][8]. - The company operates with a disciplined capital allocation strategy focused on long-term value creation, prioritizing investments in clinical advancement and manufacturing infrastructure over promotional spending [4][5]. Operational Readiness - Psyence BioMed's recent export of PsyLabs' first clinical trial product to Australia demonstrates the operational readiness of its vertically integrated model, which reduces execution risk and enhances commercialization preparedness [3][10]. - The company maintains a debt-free production operation with GMP-compliant manufacturing capabilities, ensuring quality and regulatory compliance [6][10]. Market Dynamics - The global psychedelic drugs market is projected to reach $8.75 billion by 2031, growing at a CAGR of 13.55%, indicating a favorable environment for companies with standardized pharmaceutical manufacturing and intellectual property [7][11]. - The importance of pharmaceutical-grade supply chains is underscored by the fact that hospital pharmacies managed nearly 60% of psychedelic drug distribution in 2025 [14]. Management Changes - The appointment of Sashank Pillay to the Board of Directors is expected to enhance the company's capabilities in cultivation and production project execution, given his extensive experience in the field [12].

Core Viewpoint - Psyence Biomedical Ltd. is advancing its strategic relationship with Psyence Labs Ltd. through the exercise of a put option agreement, which involves an equity investment in PsyLabs to enhance its supply strategy for pharmaceutical-grade psychedelic compounds [1][3][7]. Transaction Overview - Psyence BioMed will acquire equity securities of PsyLabs at a fair market value, with the investment expected to strengthen the strategic alignment between the two companies [3][4]. - The Share-for-Share Exchange will involve PsyLabs issuing 2,900 shares valued at US$5,000,000, while Psyence BioMed will issue 1,146,159 common shares based on a 30-day VWAP of US$4.36 per share [5][6]. - No cash will be exchanged in this transaction, and following the issuance of shares, PsyLabs will own approximately 49.98% of Psyence BioMed's outstanding common shares [6][5]. Strategic Context - The exercise of the put option is seen as a step towards securing high-quality manufacturing capabilities while maintaining capital allocation discipline as Psyence BioMed's development programs progress [7]. Governance - A Special Committee of independent directors reviewed and ratified the transaction, considering the commercial rationale and an independent valuation of PsyLabs [8]. About PsyLabs - PsyLabs is a federally licensed company specializing in the development of psychedelic Active Pharmaceutical Ingredients (APIs), including psilocybin and ibogaine, and has successfully exported products to various countries [9][10]. - The company operates from an ISO 22000-certified facility, ensuring high safety and traceability standards [11]. About Psyence BioMed - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psychedelic therapeutics, specifically psilocybin and ibogaine, to address unmet mental health needs [11].

Table of Contents As filed with the U.S. Securities and Exchange Commission on February 17, 2026. Registration No. 333-290086 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OPTIMI HEALTH CORP. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organi ...

Core Viewpoint - Psyence Biomedical Ltd. has entered into a Put Option Agreement with PsyLabs, positioning the company for significant future equity participation in a leading manufacturer of pharmaceutical-grade psychedelics, ensuring a reliable supply as commercialization progresses [1][3]. Group 1: Put Option Agreement Details - The Put Option Agreement allows PsyLabs to require Psyence BioMed to make further equity investments through a share-for-share exchange at fair market value, forming part of a broader strategic relationship [2][4]. - This agreement provides Psyence BioMed with a structured opportunity to acquire a significant equity stake in PsyLabs while securing a reliable supply of pharmaceutical-grade psychedelics for future clinical programs [3][4]. Group 2: Strategic and Commercial Benefits - The agreement enhances Psyence BioMed's clinical development pathway by mitigating supply-chain and regulatory risks, allowing the company to maintain financial flexibility without significant upfront capital deployment [4][5]. - PsyLabs is recognized as one of the most advanced manufacturers of pharmaceutical-grade psychedelic compounds, with expertise in scalable, GMP-compliant production [3][6]. Group 3: Company Background - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies to address unmet mental health needs, being the first of its kind listed on Nasdaq [8]. - PsyLabs is federally licensed to cultivate and export various psychedelic compounds, including psilocybin and ibogaine, to legal medical and research markets, with successful exports to multiple countries [6][7].

Core Viewpoint - Optimi Health Corp. is implementing equity compensation and marketing initiatives to support its growth strategy and enhance market awareness [1] Equity Incentive Grants - The company has approved the grant of 850,000 stock options and 555,000 restricted share rights to directors, officers, employees, and key individuals [2] - The stock options are exercisable for five years at an exercise price of $0.50 per common share, while the restricted share rights will convert into common shares without additional consideration [3] Marketing and Sponsored Research Initiatives - Optimi has entered into a research sponsorship agreement with Diamond Equity Research LLC to provide independent research coverage, including an initiation report and financial valuation model [4] - Research coverage will be distributed through various financial and social media platforms such as FactSet, LinkedIn, Yahoo Finance, and Google Finance [5] Marketing and Investor Awareness Services - The company has engaged Native Ads Inc. for investor awareness and promotional services, with a digital media campaign set to begin in Q1 2026 and last up to 24 months [6] - A budget of up to US$350,000 has been approved for the digital advertising campaign aimed at increasing awareness of the company's MDMA and psilocybin products [7][8] Company Overview - Optimi Health Corp. is a GMP-compliant pharmaceutical drug manufacturer licensed by Health Canada, operating from two facilities in British Columbia [9]

Core Insights - Psyence Biomedical Ltd. has achieved a significant milestone by becoming the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride derived from ethically sourced materials in Africa [2][3] - The production of ibogaine HCl enhances the stability, solubility, purity, and dosing precision of the compound, aligning it with pharmaceutical development requirements [2] - The company is well-positioned for growth entering 2026, with a cash balance of $12 million, no debt, and a Phase 2b psilocybin clinical trial in progress [3] Company Developments - The CEO of Psyence BioMed emphasized that the successful production of GMP-compliant ibogaine HCl supports the company's vertically integrated strategy and long-term objectives [3] - A change in the Board of Directors occurred with the resignation of Christopher Bull and the appointment of Graham Patrick, who brings extensive experience in governance and compliance [4] Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine-based psychedelic therapeutics [5] - The company aims to address unmet mental health needs through evidence-based approaches and is committed to developing FDA-approved treatments for various mental health disorders [5]

Core Insights - Psyence Biomedical Ltd. is the first publicly listed company to investigate the potential impact of psilocybin on longevity, collaborating with researchers in South Africa [1][6] - The initiative aims to explore psilocybin's effects on biological markers associated with aging, which could redefine human longevity and transform aging [1][6] Industry Context - Longevity science is gaining global attention due to aging populations and rising healthcare costs, with public figures like Bryan Johnson promoting psychedelic therapies for longevity [2][6] - Scientific literature supports the intersection of psychedelics and aging biology, with preclinical research indicating that psilocin can extend survival in aged mouse models and increase the lifespan of human cells by over 50% [2] Research Initiative - Psyence BioMed is developing a preclinical protocol to evaluate psilocybin's influence on biological mechanisms related to aging, focusing on biomarkers of cellular stress, inflammation, and mitochondrial function [3] - The research will be led by Dr. Tanya Calvey, a recognized neuroscientist specializing in neuropsychopharmacology, to rigorously investigate the effects of psilocybin on aging [4][5] Strategic Positioning - The initiative complements Psyence BioMed's existing clinical programs, including psilocybin-assisted therapy trials for palliative care patients, advancing the company's mission to explore the therapeutic potential of psilocybin and ibogaine [7] - The company is positioned at the forefront of a new therapeutic arena, with significant interest in understanding how psilocybin may influence biological aging [6]